AbbVie Inc. (ABBV) Revenue by Segment & Business Profile

SKYRIZI was 32.4% of AbbVie Inc.'s revenue across the 10 lines it reports, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ABBVAbbVie Inc.Follow ABBV — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 504.8B
P/E TTM: 80.7
Dividend yield: 2.4%
52-week: —
Next earnings: 30 Oct, in 6 days

What the company does

AbbVie Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 10 business lines: SKYRIZI (32%), RINVOQ (15%), Other Products (6%), Vraylar (6%) and others. Trailing twelve-month revenue: $64.4 billion as of 2026-06-30.

Roles we read

from the filings, not the sector label

Biologics / biotech major

Revenue by geography

latest quarter · company segment note

Region	Revenue	Share	y/y
United States	12.15B	71.5%	+9.8%
Outside the US	3.47B	20.4%	+16.5%

AbbVie Inc. — questions

What does AbbVie Inc. do?: AbbVie Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 10 business lines: SKYRIZI (32%), RINVOQ (15%), Other Products (6%), Vraylar (6%) and others. Trailing twelve-month revenue: $64.4 billion as of 2026-06-30.
How does AbbVie Inc. make money?: By the lines it reports in its SEC filings: SKYRIZI 32.4%, RINVOQ 14.9%, Other Products 6.5%, Vraylar 6.3%, Botox Therapeutic 6.1% of revenue.

Every figure on this page comes from AbbVie Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.